Explore more publications!
Vatican Health Times
Got News to Share?

Vatican Health Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Vatican Health Times.

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

Press releases published on December 10, 2025

OneMedNet Reports Strong Momentum and Industry Excitement at RSNA
December 10, 2025

OneMedNet Reports Strong Momentum and Industry Excitement at RSNA

Indeterminate GlobeNewswire
Sanara MedTech Inc. and Biomimetic Innovations Provide Update on OsStic™
December 10, 2025

Sanara MedTech Inc. and Biomimetic Innovations Provide Update on OsStic™

Indeterminate GlobeNewswire
PharmAla Biotech Completes Release Testing on Australian-Made LaNeo Capsules
December 10, 2025

PharmAla Biotech Completes Release Testing on Australian-Made LaNeo Capsules

Indeterminate GlobeNewswire
FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions
December 10, 2025

FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions

Indeterminate GlobeNewswire
Commure Partners with Val Verde Regional Medical Center to Enhance Clinical Workflows with MEDITECH-Integrated Ambient AI
December 10, 2025

Commure Partners with Val Verde Regional Medical Center to Enhance Clinical Workflows with MEDITECH-Integrated Ambient AI

Indeterminate GlobeNewswire
Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds
December 10, 2025

Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds

Indeterminate GlobeNewswire
Veru to Report Fiscal Year 2025 Financial Results on December 17th
December 10, 2025

Veru to Report Fiscal Year 2025 Financial Results on December 17th

Indeterminate GlobeNewswire
Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851
December 10, 2025

Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851

Indeterminate GlobeNewswire
Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology
December 10, 2025

Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology

Indeterminate GlobeNewswire
Technomed Medical Unveils New Double and Triple Hooked Neuromonitoring Probes to Aid in Nerve Preservation
December 10, 2025

Technomed Medical Unveils New Double and Triple Hooked Neuromonitoring Probes to Aid in Nerve Preservation

Indeterminate GlobeNewswire
24/7 Market News- Kraig Labs Breakthrough Science is Pivoting to Scalable Business
December 10, 2025

24/7 Market News- Kraig Labs Breakthrough Science is Pivoting to Scalable Business

Indeterminate GlobeNewswire
SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium
December 10, 2025

SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium

Indeterminate GlobeNewswire
Ajax Therapeutics Receives Orphan Drug Designation from the U.S. FDA for AJ1-11095 for the Treatment of Myelofibrosis
December 10, 2025

Ajax Therapeutics Receives Orphan Drug Designation from the U.S. FDA for AJ1-11095 for the Treatment of Myelofibrosis

Indeterminate GlobeNewswire
NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma
December 10, 2025

NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma

Indeterminate GlobeNewswire
PetMeds Announces Holiday Collection: Wellness-Focused Gifts for Pets and the People Who Love Them
December 10, 2025

PetMeds Announces Holiday Collection: Wellness-Focused Gifts for Pets and the People Who Love Them

Indeterminate GlobeNewswire
DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility
December 10, 2025

DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility

Indeterminate GlobeNewswire
Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
December 10, 2025

Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease

Indeterminate GlobeNewswire
Accrete Health Partners Launches Partnership with Atalan to Co-develop Groundbreaking Patient Experience Intelligence Module
December 10, 2025

Accrete Health Partners Launches Partnership with Atalan to Co-develop Groundbreaking Patient Experience Intelligence Module

Indeterminate GlobeNewswire
Guardian Recovery – Princeton Detox & Recovery Center Introduces Residential Inpatient Treatment, Creating a Complete Recovery Journey for New Jersey Residents
December 10, 2025

Guardian Recovery – Princeton Detox & Recovery Center Introduces Residential Inpatient Treatment, Creating a Complete Recovery Journey for New Jersey Residents

Indeterminate GlobeNewswire
Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants
December 10, 2025

Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions